# Framework-Specific Guidance

*Part of: [Compliance Process and Stakeholders](../index.md)*

---

### SOC 2 (Service Organization Control 2)

**Target Organizations**: SaaS companies, service providers, cloud platforms

**Timeline**: 6-12 months for Type I, additional 6-12 months observation for Type II

**Key Stakeholders**:
- Management (Executive Sponsor)
- Compliance Officer (Program Lead)
- IT/Engineering (Control Implementation)
- Security Team (Technical Controls)
- External CPA Firm (Auditor)

**Process Flow Specifics**:
1. **Scoping** (Weeks 1-2):
   - Define trust services categories (Security, Availability, Processing Integrity, Confidentiality, Privacy)
   - Determine systems in scope
   - Select Type I vs Type II

2. **Readiness Assessment** (Weeks 3-8):
   - Control gap analysis
   - Risk assessment
   - Control design documentation

3. **Control Implementation** (Weeks 8-20):
   - Deploy technical and administrative controls
   - Evidence collection procedures
   - Monitoring systems

4. **Testing Period** (Type II: 6-12 months):
   - Continuous monitoring
   - Regular evidence collection
   - Control effectiveness validation

5. **Audit** (Weeks 24-28):
   - External audit engagement
   - Audit response
   - Report issuance

**Unique Considerations**:
- Type I: Point-in-time assessment (faster)
- Type II: Operating effectiveness over time (more valuable to customers)
- Common in B2B SaaS sales requirements

---

### HIPAA (Health Insurance Portability and Accountability Act)

**Target Organizations**: Healthcare providers, health plans, healthcare clearinghouses, business associates

**Timeline**: 6-18 months depending on organization size and complexity

**Key Stakeholders**:
- Privacy Officer (HIPAA Privacy Rule compliance)
- Security Officer (HIPAA Security Rule compliance)
- Compliance Committee
- Clinical Staff (PHI handlers)
- IT Department (Technical Safeguards)
- Business Associate vendors
- HHS Office for Civil Rights (Regulator)

**Process Flow Specifics**:
1. **Entity Classification** (Week 1):
   - Covered Entity vs Business Associate determination
   - Regulatory applicability assessment

2. **Privacy Rule Compliance** (Weeks 2-12):
   - Privacy policies and procedures
   - Notice of Privacy Practices
   - Authorization forms
   - Minimum necessary standard implementation
   - Patient rights procedures (access, amendment, accounting)

3. **Security Rule Compliance** (Weeks 6-20):
   - Security Risk Assessment
   - Administrative Safeguards (policies, training, workforce security)
   - Physical Safeguards (facility access, workstation security)
   - Technical Safeguards (access control, audit controls, encryption)

4. **Breach Notification Rule** (Weeks 10-14):
   - Breach assessment procedures
   - Notification protocols
   - Documentation requirements

5. **Business Associate Management** (Ongoing):
   - Business Associate Agreements (BAAs)
   - Vendor due diligence
   - Subcontractor chain management

**Unique Considerations**:
- No certification process (self-attestation)
- Severe penalties for violations ($100-$50,000+ per violation)
- State law variations
- Emphasis on PHI (Protected Health Information) lifecycle

---

### GDPR (General Data Protection Regulation)

**Target Organizations**: Any organization processing EU residents' personal data

**Timeline**: 8-18 months for comprehensive compliance

**Key Stakeholders**:
- Data Protection Officer (DPO) - mandatory for public authorities and large-scale processing
- Legal/Privacy Team
- IT/Security (technical measures)
- Marketing (consent management)
- Data Processors (vendors)
- Data Subjects (individuals)
- Supervisory Authorities (DPAs - Data Protection Authorities)

**Process Flow Specifics**:
1. **Data Mapping** (Weeks 1-6):
   - Record of Processing Activities (RoPA)
   - Data flow mapping
   - Legal basis determination
   - Data inventory

2. **Legal Compliance** (Weeks 4-12):
   - Privacy policies and notices
   - Consent management mechanisms
   - Data Processing Agreements (DPAs) with processors
   - Legitimate interests assessments (LIA)
   - Data Protection Impact Assessments (DPIA) for high-risk processing

3. **Individual Rights Implementation** (Weeks 8-16):
   - Data subject access request (DSAR) procedures
   - Right to erasure (right to be forgotten)
   - Right to rectification
   - Right to data portability
   - Right to object and restrict processing

4. **Security & Breach Management** (Weeks 10-18):
   - Appropriate technical and organizational measures
   - Breach detection and notification procedures (72-hour reporting)
   - Incident response plan

5. **Accountability & Governance** (Ongoing):
   - Documentation and record-keeping
   - Regular audits and reviews
   - DPO oversight and reporting
   - Training and awareness

**Unique Considerations**:
- Extraterritorial scope (applies globally for EU data)
- Fines up to €20M or 4% of global annual revenue
- Requires DPO for many organizations
- Emphasizes privacy by design and by default
- International data transfer restrictions (Standard Contractual Clauses, Adequacy Decisions)

---

### ISO 27001 (Information Security Management System)

**Target Organizations**: Any organization seeking to demonstrate information security management

**Timeline**: 12-18 months to certification

**Key Stakeholders**:
- Top Management (commitment and resources)
- Information Security Manager (ISMS owner)
- Risk Management Team
- IT Department (technical controls)
- All employees (awareness and compliance)
- Internal Audit
- Certification Body (external auditor)

**Process Flow Specifics**:
1. **ISMS Scope Definition** (Weeks 1-2):
   - Define ISMS boundaries
   - Identify interested parties and requirements
   - Document scope statement

2. **Risk Assessment & Treatment** (Weeks 3-10):
   - Establish risk assessment methodology
   - Identify information assets and threats
   - Assess risks (likelihood and impact)
   - Define risk treatment options
   - Select Annex A controls (93 controls in ISO 27001:2022)
   - Create Statement of Applicability (SoA)
   - Risk Treatment Plan

3. **ISMS Documentation** (Weeks 6-14):
   - ISMS policies
   - Procedures and work instructions
   - Mandatory documentation (scope, policy, SoA, risk assessment/treatment)
   - Control implementation documentation

4. **Control Implementation** (Weeks 10-24):
   - Deploy selected Annex A controls
   - Technical security controls
   - Organizational controls
   - Human resource security
   - Asset management
   - Access control
   - Cryptography, physical security, operations security
   - Communications, supplier relationships
   - Incident management, business continuity
   - Compliance controls

5. **Internal Audit** (Weeks 22-26):
   - Internal ISMS audit
   - Corrective actions
   - Management review

6. **Certification Audit** (Weeks 26-30):
   - Stage 1: Documentation review
   - Stage 2: Implementation audit
   - Certificate issuance

7. **Surveillance & Recertification** (Ongoing):
   - Annual surveillance audits
   - 3-year recertification audit

**Unique Considerations**:
- Requires formal ISMS with Plan-Do-Check-Act cycle
- Risk-based approach to control selection
- Significant documentation requirements
- International recognition
- Foundation for other ISO management system standards

---

### ISO 13485 (Medical Device Quality Management)

**Target Organizations**: Medical device manufacturers, service providers

**Timeline**: 12-24 months to certification

**Key Stakeholders**:
- Top Management (quality commitment)
- Quality Management Representative
- Regulatory Affairs
- Design & Development teams
- Manufacturing/Operations
- Post-Market Surveillance
- Notified Bodies (certification, EU)
- FDA (if marketing in US)

**Process Flow Specifics**:
1. **QMS Planning** (Weeks 1-4):
   - Quality manual development
   - Quality policy and objectives
   - Organizational structure
   - Risk management plan

2. **Process Design** (Weeks 4-12):
   - Document control procedures
   - Design and development procedures
   - Purchasing and supplier management
   - Production and service provision
   - Measurement, analysis, and improvement processes

3. **Design Controls** (Ongoing):
   - Design inputs and outputs
   - Design verification and validation
   - Design transfer
   - Design changes control

4. **Risk Management Integration** (Ongoing):
   - ISO 14971 compliance
   - Risk analysis and evaluation
   - Risk control measures
   - Residual risk evaluation
   - Risk management file

5. **Post-Market Surveillance** (Ongoing):
   - Adverse event reporting
   - Complaint handling
   - Field actions and recalls
   - Trend analysis

6. **Internal Audit & Management Review** (Ongoing):
   - Regular internal audits
   - CAPA (Corrective and Preventive Action)
   - Management review meetings

7. **Certification Audit** (Weeks 20-28):
   - Stage 1: Document review
   - Stage 2: On-site audit
   - Certificate issuance

**Unique Considerations**:
- Must comply alongside FDA regulations (21 CFR 820 in US)
- Integrates with ISO 14971 (risk management)
- Emphasizes design controls and traceability
- Post-market surveillance critical
- Often required for CE marking (Europe)

---

### FDA 21 CFR Part 11 (Electronic Records and Signatures)

**Target Organizations**: Pharmaceutical, biotech, medical device companies using electronic systems

**Timeline**: 6-12 months for system validation

**Key Stakeholders**:
- Quality Assurance (validation owner)
- IT Department (system administration)
- Regulatory Affairs
- End Users (system operators)
- FDA (inspector during inspections)

**Process Flow Specifics**:
1. **System Inventory** (Weeks 1-2):
   - Identify systems in scope (electronic records, electronic signatures)
   - Determine applicable requirements

2. **Validation Planning** (Weeks 2-4):
   - Validation Master Plan
   - System validation protocols
   - Risk assessment

3. **System Validation** (Weeks 4-16):
   - Installation Qualification (IQ)
   - Operational Qualification (OQ)
   - Performance Qualification (PQ)
   - Validation report

4. **Part 11 Controls Implementation** (Weeks 6-18):
   - Audit trails (secure, time-stamped, immutable)
   - Electronic signature controls (unique, verifiable, non-repudiation)
   - System security (access controls, authentication)
   - Data integrity controls (ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available)

5. **Procedures & Training** (Weeks 10-20):
   - SOPs for system use
   - Electronic signature procedures
   - User training and competency
   - Records retention

6. **Ongoing Compliance** (Ongoing):
   - Change control
   - Periodic review
   - Revalidation
   - Audit trail review

**Unique Considerations**:
- Part of broader GxP (Good Practice) requirements
- FDA does not certify; validates during inspections
- Focus on data integrity throughout lifecycle
- Legacy systems may require remediation or paper-hybrid processes

---

### ISO 27701 (Privacy Information Management System)

**Target Organizations**: Organizations processing personal information, especially those also pursuing ISO 27001

**Timeline**: 6-12 months (if ISO 27001 already certified), 12-18 months if starting from scratch

**Key Stakeholders**:
- Data Protection Officer / Privacy Officer
- ISMS Owner (if ISO 27001 in place)
- Legal/Compliance
- IT/Security
- HR (employee data)
- Marketing (customer data)
- Certification Body

**Process Flow Specifics**:
1. **Gap Assessment** (Weeks 1-4):
   - Assess against ISO 27701 requirements
   - Extend existing ISO 27001 ISMS (if applicable)
   - Identify privacy-specific controls

2. **PIMS Extension** (Weeks 4-12):
   - Extend ISMS scope to include privacy
   - Implement additional privacy controls
   - PII (Personally Identifiable Information) inventory
   - Roles determination (PII Controller vs PII Processor)

3. **Privacy Controls Implementation** (Weeks 8-20):
   - Implement additional controls from ISO 27701 Annex A (for PII Controllers) and Annex B (for PII Processors)
   - Privacy by design integration
   - Data minimization
   - Purpose limitation
   - Transparency controls

4. **Integration with Privacy Regulations** (Ongoing):
   - Map to GDPR, CCPA, or other privacy laws
   - Demonstrate compliance alignment

5. **Certification Audit** (Weeks 20-24):
   - Extension audit if ISO 27001 already certified
   - Full audit if standalone

**Unique Considerations**:
- Builds on ISO 27001 foundation
- Demonstrates GDPR compliance approach
- Two perspectives: PII Controller and PII Processor
- International privacy standard recognition

---

### IEC 62304 (Medical Device Software Lifecycle)

**Target Organizations**: Medical device software developers

**Timeline**: 12-24 months for full implementation

**Key Stakeholders**:
- Software Development Team
- Quality Assurance
- Regulatory Affairs
- Risk Management
- Clinical/Medical Affairs
- Notified Bodies (certification)
- FDA (if marketing in US)

**Process Flow Specifics**:
1. **Software Safety Classification** (Week 1):
   - Class A (no injury or damage possible)
   - Class B (non-serious injury possible)
   - Class C (death or serious injury possible)
   - Determines rigor of lifecycle processes

2. **Software Development Planning** (Weeks 2-4):
   - Software development plan
   - Software maintenance plan
   - Risk management plan (per ISO 14971)
   - Configuration management plan

3. **Requirements Analysis** (Ongoing per project):
   - Software requirements specification
   - Trace to system requirements
   - Trace to risk controls

4. **Architectural Design** (Ongoing per project):
   - Software architecture documentation
   - Interface specifications
   - SOUP (Software of Unknown Provenance) management

5. **Detailed Design & Implementation** (Ongoing per project):
   - Detailed design documentation
   - Coding standards adherence
   - Unit testing (Class B and C)

6. **Verification & Validation** (Ongoing per project):
   - Software verification (building the product right)
   - Software validation (building the right product)
   - Traceability analysis

7. **Release & Maintenance** (Ongoing):
   - Release procedures
   - Problem resolution
   - Change management
   - Software updates

**Unique Considerations**:
- Often required alongside ISO 13485
- Integrates with ISO 14971 risk management
- Traceability between requirements, design, tests, and risks critical
- SOUP management unique to medical devices
- Safety classification drives rigor

---

### FDA AI/ML Guidance (Artificial Intelligence/Machine Learning)

**Target Organizations**: Medical device companies developing AI/ML-enabled devices

**Timeline**: 18-36 months for AI/ML device development and validation

**Key Stakeholders**:
- AI/ML Development Team (data scientists, engineers)
- Clinical Affairs (clinical validation)
- Quality Assurance
- Regulatory Affairs
- FDA (reviewer)
- Data Management (training data)
- Post-Market Surveillance

**Process Flow Specifics**:
1. **AI/ML Algorithm Development** (Months 1-12):
   - Training data collection and curation
   - Algorithm design and training
   - Algorithm validation
   - Bias and fairness assessment
   - Explainability/interpretability measures

2. **Pre-Determined Change Control Plan (PCCP)** (Months 6-12):
   - Define anticipated modifications (SaMD Pre-Specifications)
   - Algorithm Change Protocol (ACP)
   - Performance monitoring strategy

3. **Clinical Validation** (Months 10-20):
   - Clinical study design
   - Real-world performance data
   - Subgroup analysis

4. **Regulatory Submission** (Months 18-24):
   - Premarket submission (510(k), PMA, De Novo)
   - Algorithm documentation
   - Training data documentation
   - Validation evidence
   - PCCP submission

5. **Post-Market Monitoring** (Ongoing):
   - Real-world performance monitoring
   - Retraining triggers
   - Algorithm updates per PCCP
   - Adverse event reporting

**Unique Considerations**:
- Evolving regulatory landscape
- FDA's AI/ML SaMD Action Plan
- Pre-Determined Change Control Plan allows modifications without new submissions
- Algorithm transparency and explainability expectations
- Training data quality and bias critical
- Real-world performance monitoring essential

---

### GMLP/GxP (Good Machine Learning Practice / Good Practice)

**Target Organizations**: Pharmaceutical, biotech, medical device companies using ML

**Timeline**: 12-24 months for comprehensive implementation

**Key Stakeholders**:
- Data Science/ML Teams
- Quality Assurance
- Regulatory Affairs
- IT/Infrastructure
- Clinical/Medical Affairs
- Regulatory Authorities (FDA, EMA, MHRA)

**Process Flow Specifics**:
1. **GxP Foundations** (Months 1-3):
   - Quality culture establishment
   - GxP principles training
   - Data integrity framework (ALCOA+)

2. **ML-Specific Quality System** (Months 2-6):
   - ML development procedures
   - Model validation procedures
   - Data governance for ML
   - Version control and traceability

3. **Data Management** (Ongoing):
   - Training data qualification
   - Data provenance tracking
   - Data quality assessments
   - Bias detection and mitigation

4. **Model Development & Validation** (Project-based):
   - Development documentation
   - Model validation protocols
   - Performance metrics definition
   - Validation reports

5. **Model Deployment & Monitoring** (Ongoing):
   - Model deployment procedures
   - Performance monitoring
   - Drift detection
   - Retraining procedures

**Unique Considerations**:
- Combines traditional GxP with ML-specific requirements
- Emphasis on data quality and traceability
- Model explainability and bias testing
- Continuous validation paradigm (vs. traditional fixed validation)
- Regulatory expectations still evolving

---

### EN 18031 (AI Governance Framework) - Emerging Standard

**Note**: As of 2026, this is a relatively new standard. Implementation guidance is still developing.

**Target Organizations**: Organizations developing or deploying AI systems

**Timeline**: 12-18 months (estimated)

**Key Stakeholders**:
- AI Ethics Committee
- AI Development Teams
- Risk Management
- Legal/Compliance
- Executive Leadership
- External Ethics Advisors

**Process Flow Specifics** (Preliminary):
1. **AI Governance Structure** (Months 1-3):
   - AI governance committee establishment
   - AI ethics principles definition
   - Roles and responsibilities

2. **AI Risk Management** (Months 2-6):
   - AI-specific risk assessment
   - Algorithmic bias assessment
   - Fairness and accountability measures
   - Transparency requirements

3. **AI Lifecycle Management** (Ongoing):
   - AI system inventory
   - Impact assessments
   - Monitoring and auditing
   - Incident management

4. **Stakeholder Engagement** (Ongoing):
   - User engagement
   - Affected community consultation
   - Transparency reporting

**Unique Considerations**:
- Focus on ethical AI development and deployment
- Emphasizes transparency, fairness, accountability
- Likely to evolve as AI regulations mature
- May complement or overlap with emerging AI regulations (e.g., EU AI Act)

---

---

**[← Back to Index](../index.md)**
